Kazakhstan's Anti-Cancer Drug DVC Faces Market Entry Delay Until Mid-2027

Kazakhstan's anti-cancer drug DVC is now projected to launch in mid-2027, a delay attributed to stringent clinical trial requirements. The Ministry of Science and Higher Education confirmed the first phase's completion and progression to the second. Development is ongoing, with finalization expected by mid-next year before market release.

Read the full article at Kursiv →

Headline and summary written by daryo. The full report belongs to Kursiv.